Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration with Theraclone eligible for undisclosed royalties and up to $632 in research funding and milestone payments.
Theraclone Sciences, a US-based developer of antibodies (pictured) for targeting cancer formerly known as Spaltudaq, has signed a research collaboration with US-listed drugs company Pfizer worth up to $632m.
Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration. Theraclone is eligible for undisclosed royalties and up to $632 in research funding and milestone payments.
Theraclone raised $29m in its series B round in March 2007 from Amgen Ventures, the corporate venturing unit of Amgen, and…
